This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Inclusion Criteria:

• Mean eGFR greater than or equal to 30 mL/min/1.73m2
• Clinical evidence of active kidney disease
• Treated with supportive care including an ACE inhibitor or ARB if applicable
• Willing to receive required vaccinations
• Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy

Exclusion Criteria:

• Hereditary or acquired complement deficiency
• Kidney transplant or renal replacement therapy
• History of solid organ transplant
• Other kidney disease
• History of recurrent invasive infections
• Received complement inhibitor treatments
• Active systemic viral, bacterial, or fungal infection
• Abnormal liver function